bug-bounty382
xss281
exploit100
google99
facebook93
rce92
open-source91
csrf74
ai-agents63
account-takeover61
bragging-post59
writeup59
access-control59
microsoft54
apple46
tool46
smart-contract46
ethereum45
defi45
privilege-escalation43
privacy43
ssrf40
authentication-bypass39
sqli38
llm37
web337
opinion35
automation34
sql-injection33
machine-learning32
code-generation32
infrastructure31
browser31
idor30
information-disclosure30
cve29
subdomain-takeover28
api-security27
rust26
smart-contract-vulnerability26
clickjacking25
authentication24
performance-optimization24
web-security24
macos24
vulnerability-disclosure24
solidity23
pentest23
reverse-engineering23
responsible-disclosure22
0
2/10
opinion
A psychiatrist critiques Ambien's clinical approval and research methodology, arguing that FDA-approved trials excluded the very populations most likely to use the drug (those with psychiatric comorbidities), while women were underrepresented despite slower drug metabolism leading to driving impairment and accident risk.
pharmaceutical-safety
clinical-research
drug-approval
fda
zolpidem
study-design-critique
adverse-effects
gender-bias-in-research
psychiatric-comorbidity
tolerance-and-dependence
Ambien
zolpidem
FDA
Searle
Owen Scott Muir
NIDA
NIH